Treatment of hyperuricemias
Asymptomatic hyperuricemia (AH) and other disorders associated with uric acid (UA) are treated differently according to the patient’s clinical state and to the stage of renal disease (RD). There is a relation between UA level, high blood pressure (HBP), age, cardiovascular disease (CVD) and RD. The...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Asociación Regional de Diálisis y Trasplantes Renales de Capital Federal y Provincia de Buenos Aires
2017-06-01
|
| Series: | Revista de Nefrología, Diálisis y Trasplante |
| Subjects: | |
| Online Access: | http://www.revistarenal.org.ar/index.php/rndt/article/view/143 |
| Summary: | Asymptomatic hyperuricemia (AH) and other disorders associated with uric acid (UA) are treated differently according to the patient’s clinical state and to the stage of renal disease (RD). There is a relation between UA level, high blood pressure (HBP), age, cardiovascular disease (CVD) and RD. The causation of this relation is still controversial, as well as the role of UA in the onset, progression and development of RD and transplantation. The different drugs used for UA disorders therapy may be classified according to their anti-inflammatory effect in an acute episode; their prophylaxis to avoid recurrence, and their action to prevent or reverse complications caused by urate crystal depositions in the
joints (gouty arthritis), in the urinary tract (lithiasis, tubulointerstitial nephritis) and in the tissues (tophi). It is vital to keep plasma rate levels below 6.8 mg/dL; lower concentrations may be associated with better progress in gouty patients: fewer episodes, faster reduction of tophus size and absence of monosodium urate crystals in synovial fluid. |
|---|---|
| ISSN: | 0326-3428 2346-8548 |